SCHEMBL30265383

SCHEMBL30265383

O=C(c1ccc2nc[nH]c2c1)N(CCO)CCO

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.55
HTT P42858 3/20 0.54
RAB9A P51151 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HPGD P15428 1/20 0.54
CTNNB1 P35222 2/20 0.53
WNT3A P56704 2/20 0.53
L3MBTL1 Q9Y468 4/20 0.49
CTDSP1 Q9GZU7 2/20 0.49
POLB P06746 4/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 2/20 0.47
MEN1 O00255 1/20 0.47
CASP6 P55212 2/20 0.45
MAPK1 P28482 1/20 0.45
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007147 0.84 HDAC6 (0.56) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL4961972 0.79 HDAC6 (0.60) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL17802748 0.77 HDAC6 (0.55) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL30265092 0.77 HDAC6 (0.57) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL5946 0.75 RAB9A (0.71) HDAC6HTTRAB9ASMN1; SMN2KDM4E
Alcohol SCHEMBL28171577 0.75 RAB9A (0.61) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL6017092 0.74 HDAC6 (0.55) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL30265434 0.74 HTT (0.72) HDAC6HTTRAB9ASMN1; SMN2L3MBTL1
SCHEMBL3727881 0.74 HDAC6 (0.58) HDAC6HTTRAB9ASMN1; SMN2KDM4E
SCHEMBL1534631 0.74 HDAC6 (0.55) HDAC6HTTRAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034107-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS VTV THERAPEUTICS LLC (US) 2026-02-05 US disclosed
US-20230093476-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS VTV THERAPEUTICS LLC 2023-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230093476-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS ALDH1A2, UACA, PDE6D HDAC6 154/4885HTT 4721/4885RAB9A 359/4885
US-20260034107-A1 SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS HBB, HBZ, HBG1 HDAC6 1346/4885HTT 311/4885RAB9A 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.